Life-sciences-focused investor led a $42m Series B round in Nomic Bio.

Life-sciences-focused investor led a $42m Series B round in Nomic Bio, the Protein Profiling company, with participation from Amplitude Ventures, AVANT BIO, Lux Capital, Real Ventures, and SR One. “Nomic was founded to help scientific teams succeed in their mission to extend health spans. We’re excited to see our technology embraced by some of the most innovative R&D teams and to witness the nELISA platform advance critical drug discovery efforts. As we set out to greatly increase our biological footprint alongside unlocking several new applications, we are energized to partner with a distinguished group of investors who share our bold vision,” Milad Dagher, Nomic CEO and Co-founder.